We tackle the big question: what does the acceleration of remote and digital engagement mean exactly, and what opportunities does it present for the industry to reimagine its future?
Just a few short months ago, it was business as usual for the pharmaceutical industry. COVID-19 has drastically challenged the agility and flexibility of the pharma industry to adapt to lockdown conditions. Now, businesses and their service partners must continue working closely beyond the pandemic to develop a new way of working that places heightened emphasis on HCP preference.
This whitepaper consolidates real data from HCPs on their new perspectives alongside applications for optimizing omnichannel engagement strategies as well as patient engagement programs.
- Utilizing a channel mix that meets the new preferences of HCPs and patients
- Breaking through ramped up levels of digital noise
- Maintaining face-to-face relationships
- Responding to patients who have embraced virtual support visits